-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 15, 2021, Novocure announced the latest data from a Phase 2 clinical trial
When cancer develops, cancerous cells divide rapidly and uncontrollably, and the charged proteins in the cells make the cells susceptible to electric field interference
Compared with traditional treatment methods, tumor electric field treatment has the advantages of convenience, non-invasiveness and fewer side effects.
picture
▲The mechanism of tumor electric field therapy (picture source: Novocure official website)
The Phase 2 trial enrolled 25 adult patients with glioblastoma (median age 61 years), and the median follow-up time was 14.
The test data showed that among the 19 patients who were followed up for more than 9 months, the PFS of the patients reached at least 11.
Reference materials:
[1] 2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma.